메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Siemens Healthineers Receives Frost & Sullivan's 2025 North Am…

[ 메디채널 김갑성 기자 ] Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions SAN ANTONIO, July 28, 2025 -- Frost & Sullivan is pleased to announce that Siemens Healthineers has been awarded the 2025 North America Company of the Year Recognition in the advanced visualization applications industry for its outstanding achievements in diagnostic innovation, seamless platform integration, and customer impact. This recognition underscores Siemens Healthineers' market leadership in transforming medical i
- 김갑성 기자
- 2025-07-28 22:00
XellSmart Completed World's First Patient Dosing in its Registrati…

SUZHOU, China, July 28, 2025 -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational clinical trial. This Phase I China registrational clinical trial for XS228 Cell Injection – the world's first "off-the-shelf", allogeneic, iPSC-derived, spinal neural progenitor cell therapy targeting major neurological disorders, specifically spinal cord injury (SCI) – has commenced. The clinical trial initiation meeting was held at The Third Affiliated Hospital of Sun Yat-sen Univer
- 김갑성 기자
- 2025-07-28 21:10
World's First Engineered Exosome for Hair Growth & Localized…

SUZHOU, China, July 28, 2025 -- ImmVira Group ("ImmVira" or the "Company")recently announced that its engineered exosome products MVR-EX104 ("EX104", for alopecia treatment) and MVR-EX105 ("EX105", for localized fat accumulation) have obtained International Nomenclature of Cosmetic Ingredients (INCI) designations following review by the International Cosmetic Ingredient Nomenclature Committee (INC). This dual milestone underscores ImmVira's breakthrough leadership in functional aesthetic ingredients, bring forward revolutionary consumer healthca
- 김갑성 기자
- 2025-07-28 20:28
Alamar Biosciences Showcases Pioneering Brain-Derived p…

[ 메디채널 김갑성 기자 ] Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform is poised to redefine the landscape of biomarker detection, offering unprecedented sensitivity, specificit
- 김갑성 기자
- 2025-07-28 20:12
알라마 바이오사이언스, 알츠하이머 협회 국제학술대회(AAIC)에서 획기적인 뇌 유래 pTa…

[ 메디채널 김갑성 기자 ] 신경퇴행성 질환 바이오마커 연구의 새로운 지평 - 30개 이상의 포스터 및 프레젠테이션 통해 공개 프리몬트, 캘리포니아, 2025년 7월 28일 -- 정밀 단백체학을 기반으로 질병의 조기 진단을 선도하고 있는 알라마 바이오사이언스(Alamar Biosciences)가 자사의 NULISA™ 플랫폼 관련 데이터를 7월 27일부터 31일까지 캐나다 토론토에서 열리는 알츠하이머 협회 국제학술대회(Alzheimer's Association International Conference, AAIC)에서 30건 이상의 학술 세션과 포스터 발표를 통해 공개한다고 밝혔다. NULISA 플랫폼은 신경퇴행성 질환 진단 및 모니터링을 위한 바이오마커 검출 분야에서 감도, 특이성, 다중 분석 능력 측면에서 새로운 기준을 제시할 것으로 기대된다. 올해 AAIC에서는 NULISA를 사용하여 뇌유래 pTau와 120개 이상의 주요 중추신경계(CNS) 질환 관련 단백질에 대한 강력한 임상 데이터가 처음으로 공개된다. 이는 알츠하이머병 및 관련 신경퇴행성 질환의 조기 발견과 치료 모니터링을 가속화할 수 있는 중대한 성과로 평가된다.
- 김갑성 기자
- 2025-07-28 20:12
Antengene Announces XPOVIO® Approved in China for the Se…

- This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug in China.- XPOVIO® as a monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and in combination with dexamethasone in patients with R/R MM, two of the three approved indications of XPOVIO® in China, have already been included into China's National Reimbursement Drug List.- Results from the BENCH study
- 김갑성 기자
- 2025-07-28 18:49
Interventional Robot's RCT Research Published in JNIS, a Le…

SHANGHAI, July 28, 2025 -- The multicenter, randomized controlled trial (RCT) results of the PANVIS-A® NeuroInterventional Robotic System—led by Professor Liu Jianmin (Changhai Hospital) in collaboration with Professor Sun Jun (Wenzhou Central Hospital), Professor Chen Wenhuo (Zhangzhou Municipal Hospital of Fujian Province), and Professor Cheng Guangsen (Zhuhai People's Hospital)—have been officially published in the Journal of NeuroInterventional Surgery (JNIS). This milestone marks the first time a China-developed vascular-interventional robot has gained recognition from a premier inte
- 김갑성 기자
- 2025-07-28 18:35
Embolx Launches Sniper G3: Revolutionizing Embolization w…

SUNNYVALE, Calif., July 28, 2025 -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third iteration of the innovative device delivers significant enhancements, including an extended shelf life, improved ease of use, and streamlined preparation, directly addressing critical feedback from physician users. The highly anticipated Sniper G3 features a 24-month shelf life, doubling the longevity of its predecessor. This improvement offers greater invent
- 김갑성 기자
- 2025-07-28 18:00
Caliway Announces FDA Clearance of IND Application for CBL-…

CBL-514, Caliway's first-in-class lipolysis drug candidate, has been granted clearance from the U.S. FDA to proceed with SUPREME-01, a global, multicenter, pivotal Phase 3 study. Subject recruitment is expected to begin in the U.S. and Canada in Q3 2025. CBL-514 is the first 505(b)(1) investigational drug with FDA clearance to proceed with a Phase 3 study for the proposed indication of "Reduction of Abdominal Subcutaneous Fat." Caliway also plans to submit regulatory applications for its second global pivotal Phase 3 study, SUPREME-02, in the U.S., Canada, and Australi
- 김갑성 기자
- 2025-07-28 17:51
Precision Orthopedic Surgery in Asia: Addressing Regiona…

TAIPEI, July 28, 2025 -- The Malaysian Orthopedic Association (MOA), Aclub Taiwan, and A Plus Biotechnology Corporation Limited will co-host a high-level academic conference on August 3, 2025, at Sunway Medical Centre in Kuala Lumpur, bringing together orthopedic professionals from across Asia to explore the latest advances in personalized, minimally invasive orthopedic surgery. The event will feature both in-person and online participation options. As Asia's active population grows and patient expectations evolve, the demand for personalized, minimally invasive orthopedic solu
- 김갑성 기자
- 2025-07-28 17:32

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분